Screener
BioMarin Pharmaceuticals BMRN Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Accounts payable and accrued operating expenses | $406,977 | $312,768 |
| Accrued rebates payable | 243,526 | 166,925 |
| Accrued compensation expense | 220,506 | 219,422 |
| Accrued Interest | 47,129 | 907 |
| Foreign currency exchange forward contracts | 33,525 | 31,007 |
| Lease liability | 16,058 | 8,685 |
| Accrued royalties payable | 15,502 | 7,968 |
| Accrued income taxes | 9,137 | 3,667 |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's accrued expenses?
- BioMarin Pharmaceuticals (BMRN) reported accrued expenses of $220.51M in Q2 2026.
- How has BioMarin Pharmaceuticals's accrued expenses changed year-over-year?
- BioMarin Pharmaceuticals's accrued expenses increased by 84.7% year-over-year, from $119.41M to $220.51M.
- What is the long-term trend for BioMarin Pharmaceuticals's accrued expenses?
- Over 5 years (2020 to 2025), BioMarin Pharmaceuticals's accrued expenses has grown at a 5.9% compound annual growth rate (CAGR), from $165.02M to $219.42M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about BioMarin Pharmaceuticals's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude